Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
A Randomised, Placebo-controlled Trial of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause in which areas of normal
lung tissue are replaced by scars. As a result it becomes harder for the lungs to extract
oxygen from the air. IPF is commonly progressive, and around 50% of patients diagnosed with
the disease die after approximately 3 years. The most common, troublesome symptoms of IPF are
breathlessness on exertion, and cough. No drug treatments have been unequivocally shown to
improve the death rate, or to significantly impact upon symptoms, in IPF.
In recent years it has been recognised that cough can be caused by small amounts of liquid
coming up from the stomach and "going down the wrong way" into the lungs, a process commonly
known as "reflux". As liquid in the stomach is usually acidic, patients' lungs may repeatedly
be exposed to small amounts of acid. Reflux is unusually common in IPF and could potentially
contribute to the debilitating cough found with the disease. However there are many potential
causes for cough in IPF.
Stomach acid can be efficiently "switched off" by drugs called "proton pump inhibitors", one
of which is called omeprazole. If reflux of stomach acid does contribute to cough in IPF,
omeprazole might be expected to reduce cough. The purpose of this study is therefore to test
whether omeprazole does reduce cough in patients with IPF. Sixty patients with IPF will be
randomly allocated to have 3 months of omeprazole or a placebo. Neither the patient nor the
doctor will be aware which treatment has been given, ie this is a randomised "double-blind",
placebo--controlled trial. Patients' cough frequency will be measured before and after
treatment and the change in cough frequency compared in those receiving omeprazole and those
receiving placebo. Change in cough frequency is the main thing we aim to compare, but a range
of other measurements will be assessed such as the numbers of patients eligible to take part,
agreeing to randomisation and providing outcome data, patients' lung function, symptom
scores, the amount of reflux, and the amount of inflammation in the lungs.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
Completed |
NCT00532233 -
SD, IL-13 Production Rate in IPF
|
Phase 2 | |
Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|